Appili Therapeutics Inc.
APLI.TO
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 2,176.47% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2,176.47% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 2,176.47% | -- | |||
| SG&A Expenses | -32.99% | -14.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.88% | -2.44% | |||
| Operating Income | 25.65% | 2.61% | |||
| Income Before Tax | 29.87% | 53.01% | |||
| Income Tax Expenses | -888.89% | -- | |||
| Earnings from Continuing Operations | 31.28% | 52.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 31.28% | 52.94% | |||
| EBIT | 25.65% | 2.61% | |||
| EBITDA | 25.72% | 2.59% | |||
| EPS Basic | 31.11% | 53.13% | |||
| Normalized Basic EPS | 28.57% | 53.33% | |||
| EPS Diluted | 31.11% | 53.13% | |||
| Normalized Diluted EPS | 28.57% | 53.33% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
